Pulmonary Hypertension Trial, Recruiting NCT07576894 Sponsor: University of Colorado, Denver Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT07576894
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with COPD, confirmed by a specific breathing test result (where the FEV1/FVC ratio is less than 0.7)
  • People who are 40 years of age or older

Who may not be able to join:

  • People who had a COPD flare-up or worsening episode in the 3 months before enrolling
  • People whose COPD medications were changed in the 3 weeks before enrolling
  • People who need more than 6 litres per minute of supplemental oxygen while at rest
  • People who need more than 10 litres per minute of supplemental oxygen during physical activity
  • People with active or poorly controlled heart conditions, such as: high blood pressure above 150/100 even with medication, chest pain from coronary artery disease, weak heart pumping function, uncontrolled irregular heartbeat, more than mild heart valve problems, or more than moderate leaking of the tricuspid heart valve
  • People with signs of fluid build-up in the body, such as swelling in the neck veins or more than slight swelling in the legs or feet
  • People who are classified as World Health Organization Functional Class IV, meaning their symptoms are severely limiting even at rest (confirm with trial site)
  • People with known pulmonary hypertension (high blood pressure in the lungs) where the average pressure in the main lung artery is above 45 mmHg
  • People with untreated severe sleep apnoea and/or a condition where obesity affects breathing during sleep
  • People with an active cancer (other than skin cancer)
  • People with physical conditions that would prevent them from exercising on an upright stationary bike, such as severe joint problems or balance and walking difficulties
  • People who are pregnant
  • People whose body mass index (a measure of weight relative to height) is below 18 or above 35
  • People whose blood thickness level (haematocrit) is below 25% or above 55%
  • For the group having a right heart catheterisation (a procedure to measure pressures in the heart): people who take blood thinners that cannot be safely stopped for the study visit
  • For the group having a right heart catheterisation or exercise training: people whose breathing test shows lung function below 20% of expected
  • For the exercise training part: people who are already doing regular exercise training (more than 30 minutes at a moderate intensity, 3 or more times per week)
  • For the exercise training part: people who are unable to attend in-person exercise sessions of approximately 35 minutes, 3 times per week, for 3 weeks at the start of the program
  • For the hybrid remote exercise training option: people with any health conditions that would make exercising at home unsafe, such as balance or walking difficulties

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lindsay Forbes, MD, University of Colorado, Denver

Phone: (303)724-4020

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 May 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Right ventricular contractility measured by transthoracic echocardiography

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov